Patients should be considered for
therapy if they meet the inclusion criteria
of established guidelines for treatment
of either HBV or HCV monoinfection. In patients with HCV-dominant disease, peginterferon plus ribavirin would be the best choice of therapy given the experience with peginterferon in hepatitis C patients and the published studies of interferon plus ribavirin in the coinfected population.